Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma

Johannes J. A. Auwerda; Yuana Yuana; Susanne Osanto; Moniek P. M. de Maat; Pieter Sonneveld; Rogier M. Bertina; Frank W. G. Leebeek

doi:10.1160/TH10-03-0187

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2011; 105(01): 14-20
DOI: 10.1160/TH10-03-0187

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma

Johannes J. A. Auwerda

¹Department of Hematology, Erasmus University Medical Center Rotterdam, the Netherlands

,

Yuana Yuana

²Department of Clinical Oncology, Leiden University Medical Center, Leiden, the Netherlands

,

Susanne Osanto

²Department of Clinical Oncology, Leiden University Medical Center, Leiden, the Netherlands

,

Moniek P. M. de Maat

¹Department of Hematology, Erasmus University Medical Center Rotterdam, the Netherlands

,

Pieter Sonneveld

¹Department of Hematology, Erasmus University Medical Center Rotterdam, the Netherlands

,

Rogier M. Bertina

³Einthoven Laboratory for Experimental Vascular Medicine, Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands

,

Frank W. G. Leebeek

¹Department of Hematology, Erasmus University Medical Center Rotterdam, the Netherlands

› Author Affiliations

Abstract

Summary

Multiple myeloma (MM) is associated with an increased risk of venous thromboembolic (VTE) complications. Aim of this study was to measure microparticle-associated tissue factor (MP-TF) activity in patients with newly diagnosed MM before and after chemotherapy and to investigate whether MP-TF activity is associated with VTE. MP-TF activity was assessed in 122 newly diagnosed MM patients who were eligible for combination chemotherapy. MP-TF activity levels (17.6 fM Xa/min [8.6–33.2] (median [IQR]) were higher in untreated MM patients compared to normal healthy volunteers (4.1 fM Xa/min [2.3–6.6], p <0.001). MP-TF activity prior to the start of treatment was not different between patients who developed a VTE during follow-up (n=15) and those who did not (n=107). In 75 patients in whom plasma was obtained before and after chemotherapy, MP-TF activity decreased significantly (from 17.4 [10.2–32.8] to 12.0 [7.0–18.5] fM Xa/min, P=0.006). MP-TF activity remained, however, elevated in patients who developed VTE (15.1 [10.3–25.2]), in contrast to patients not developing VTE (11.4 [7.0–25.2], P<0.001). In conclusion, MP-TF activity is increased in patients with MM. Whether MP-TF activity has a pathogenetic role in VTE in MM patients remains to be established in future studies.

Keywords

Multiple myeloma - tissue factor - microparticles - venous thrombosis

Full Text

References

References
1 Zangari M, Elice F, Fink L. et al. Thrombosis in multiple myeloma. Expert Rev Anticancer Ther 2007; 07: 307-315.
2 Palumbo A, Rajkumar SV, Dimopoulos MA. et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-423.
3 Auwerda JJ, Sonneveld P, de Maat MP. et al. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 2007; 92: 279-280.
4 Minnema MC, Fijnheer R, De Groot PG. et al. Extremely high levels of von Wille-brand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 01: 445-449.
5 Elice F, Fink L, Tricot G. et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006; 134: 399-405.
6 van Marion AM, Auwerda JJ, Minnema MC. et al. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost 2005; 94: 1341-1343.
7 Jimenez VHs, Dominguez VJs. Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb J 2006; 04: 11.
8 Giesen PL, Rauch U, Bohrmann B. et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-2315.
9 Morel O, Toti F, Hugel B. et al. Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol 2004; 11: 156-164.
10 Kakkar AK, Lemoine NR, Scully MF. et al. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995; 82: 1101-1104.
11 Uno K, Homma S, Satoh T. et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer 2007; 96: 290-295.
12 Wojtukiewicz MZ, Sierko E, Klement P. et al. The hemostatic system and angio-genesis in malignancy. Neoplasia 2001; 03: 371-384.
13 Khorana AA, Ahrendt SA, Ryan CK. et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007; 13: 2870-2875.
14 Tesselaar ME, Romijn FP, Van Der Linden IK. et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost 2007; 05: 520-527.
15 Manly DA, Wang J, Glover SL. et al. Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res 2010; 125: 511-512.
16 Zwicker JI, Liebman HA, Neuberg D. et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15: 6830-6840.
17 Toth B, Liebhardt S, Steinig K. et al. Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost 2008; 100: 663-669.
18 Zwicker JI. Predictive value of tissue factor bearing microparticles in cancer associated thrombosis. Thromb Res 2010; 125 (Suppl. 02) S89-91.
19 Khorana AA, Francis CW, Menzies KE. et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008; 06: 1983-1985.
20 Tesselaar ME, Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med 2007; 13: 362-367.
21 Hron G, Kollars M, Weber H. et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97: 119-123.
22 Kyle RA. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am 1992; 06: 347-358.
23 Greipp PR, San Miguel J, Durie BG. et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
24 Durie BG, Salmon SE. Cellular kinetics staging, and immunoglobulin synthesis in multiple myeloma. Annu Rev Med 1975; 26: 283-288.
25 Vanwijk MJ, Svedas E, Boer K. et al. Isolated microparticles, but not whole plasma, from women with preeclampsia impair endothelium-dependent relaxation in isolated myometrial arteries from healthy pregnant women. Am J Obstet Gynecol 2002; 187: 1686-1693.
26 Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 2003; 124 (Suppl. 03) 58S-68S.
27 Mueller BM, Reisfeld RA, Edgington TS. et al. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992; 89: 11832-11836.
28 Kakkar AK, DeRuvo N, Chinswangwatanakul V. et al. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995; 346: 1004-1005.
29 Sase T, Wada H, Yamaguchi M. et al. Haemostatic abnormalities and thrombotic disorders in malignant lymphoma. Thromb Haemost 2005; 93: 153-159.
30 Sase T, Wada H, Kamikura Y. et al. Tissue factor messenger RNA levels in leukocytes compared with tissue factor antigens in plasma from patients in hyper-coagulable state caused by various diseases. Thromb Haemost 2004; 92: 132-139.
31 Negaard HF, Iversen PO, Ostenstad B. et al. Hypercoagulability in patients with haematological neoplasia: No apparent initiation by tissue factor. Thromb Haemost 2008; 99: 1040-1048.
32 Shimizu K, Itoh J. A possible link between Trousseau‘s syndrome and tissue factor producing plasma cells. Am J Hematol 2009; 84: 382-385.
33 Key NS, Chantrathammachart P, Moody PW. et al. Membrane microparticles in VTE and cancer. Thromb Res 2010; 125 (Suppl. 02) S80-83.
34 Palumbo A, Bringhen S, Caravita T. et al. Oral melphalan and prednisone chemo-therapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825-831.
35 Zangari M, Barlogie B, Anaissie E. et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126: 715-721.
36 Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 2006; 95: 924-930.
37 Zangari M, Barlogie B, Thertulien R. et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma 2003; 04: 32-35.

Supplementary Material

Online Supplementary Material (PDF)